These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22173961)

  • 1. Achievements in CKD-MBD guidelines targets: is there a progress in the implementation practice?
    Spasovski G; Zdravkovska V; Zabzun M; Antarorov R; Ivanovski K; Janakievska P; Neskovski J; Karceva-Sarajlia E; Panova B; Petrovska T; Zulbeari L; Masin-Spasovska J; Taleska-Matovska N; Gelev S
    Int Urol Nephrol; 2012 Dec; 44(6):1791-8. PubMed ID: 22173961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of biochemical disturbances of chronic kidney disease - mineral and bone disorders (CKD-MBD) in a nation-wide peritoneal dialysis cohort: are guideline goals too hard to achieve?
    Weissheimer R; Bucharles SGE; Truyts CAM; Jorgetti V; Figueiredo AE; Barrett P; Olandoski M; Pecoits-Filho R; Moraes TP
    J Bras Nefrol; 2021; 43(2):173-181. PubMed ID: 33538758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between Hemodialysis Patient Outcomes and Compliance with KDOQI and KDIGO Targets for Mineral and Bone Metabolism.
    Djukanović L; Dimković N; Marinković J; Djurić Ž; Knežević V; Lazarević T; Ljubenović S; Marković R; Rabrenović V
    Nephron; 2016; 132(3):168-74. PubMed ID: 26914677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineral and bone disorder in hemodialysis patients in the Tibetan Plateau: a multicenter cross-sectional study.
    Dang ZH; Tang C; Li GL; Luobu C; Qing D; Ma ZH; Qu JF; Suolang L; Liu LJ
    Ren Fail; 2019 Nov; 41(1):636-643. PubMed ID: 31269846
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
    Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
    J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic hemodialysis patients without marked elevation of intact parathyroid hormone are also good candidates for early intervention with cinacalcet.
    Nishida H; Masakane I; Kudo K; Ito M; Tanida H; Koshika M; Nishida W; Tomita Y
    Ther Apher Dial; 2013 Jun; 17(3):325-31. PubMed ID: 23735149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Status of Serum Calcium, Phosphate and Intact Parathyroid Hormone in Predialysis Chronic Kidney Disease Patients of Stage-3 to Stage-5 Compared To KDOQI Guideline.
    Hai AA; Rahman MM; Anwar MR; Miah OF; Latif A; Jalil ME; Razzak MA; Morshed AM; Mahmud H; Dowel FA
    Mymensingh Med J; 2021 Oct; 30(4):1031-1042. PubMed ID: 34605474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice.
    Toussaint ND; Pedagogos E; Beavis J; Becker GJ; Polkinghorne KR; Kerr PG
    Nephrol Dial Transplant; 2011 Apr; 26(4):1319-26. PubMed ID: 20935019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).
    Uhlig K; Berns JS; Kestenbaum B; Kumar R; Leonard MB; Martin KJ; Sprague SM; Goldfarb S
    Am J Kidney Dis; 2010 May; 55(5):773-99. PubMed ID: 20363541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation on maintenance hemodialysis patients with mineral and bone disorder in Anhui province, China.
    Tao S; Li X; Liu Z; Bai Y; Qian G; Wu H; Li J; Guo Y; Yang S; Chen L; Yang J; Han J; Ma S; Yang J; Yu L; Shui R; Jin X; Wang H; Zhang F; Chen T; Li X; Zong X; Liu L; Fan J; Wang W; Zhang Y; Shi G; Wang D
    Int Urol Nephrol; 2023 Feb; 55(2):389-398. PubMed ID: 35951256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
    Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
    Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International variation in the management of mineral bone disorder in patients with chronic kidney disease: Results from CKDopps.
    Liabeuf S; McCullough K; Young EW; Pisoni R; Zee J; Reichel H; Pecoits-Filho R; Port FK; Stengel B; Csomor PA; Metzger M; Robinson B; Massy ZA
    Bone; 2019 Dec; 129():115058. PubMed ID: 31493530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.
    Tangri N; Wagner M; Griffith JL; Miskulin DC; Hodsman A; Ansell D; Naimark DM
    Am J Kidney Dis; 2011 Mar; 57(3):415-21. PubMed ID: 21131115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
    Isakova T; Nickolas TL; Denburg M; Yarlagadda S; Weiner DE; Gutiérrez OM; Bansal V; Rosas SE; Nigwekar S; Yee J; Kramer H
    Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of switching to nocturnal thrice-weekly hemodialysis on clinical and laboratory parameters: our experience.
    Gubenšek J; Buturović-Ponikvar J; Knap B; Marn Pernat A; Benedik M; Ponikvar R
    Ther Apher Dial; 2013 Aug; 17(4):412-5. PubMed ID: 23931881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The current status of chronic kidney disease-mineral and bone disorder management in China.
    Zhan Y; He X; Hong D; Wang L; Li G
    Sci Rep; 2022 Oct; 12(1):16694. PubMed ID: 36202866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D.
    Yusuf AA; Howell BL; Powers CA; St Peter WL
    Am J Kidney Dis; 2014 Nov; 64(5):770-80. PubMed ID: 24833203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium, phosphate and parathyroid metabolism in kidney transplanted patients.
    Ambrus C; Molnar MZ; Czira ME; Rosivall L; Kiss I; Remport A; Szathmari M; Mucsi I
    Int Urol Nephrol; 2009 Dec; 41(4):1029-38. PubMed ID: 19701690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.